Is there a need for pharmacokinetically guided carboplatin dose schedules?

Oncology Research and Treatment

Volumn 20, Issue 4, 1997, Pages 343-345

  Bokemeyer, C ^a   Lipp, H P ^b  

^a Medizinische Klinik und Poliklinik   (United States)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ETOPOSIDE;

CANCER CHEMOTHERAPY; DRUG MEGADOSE; GLOMERULUS FILTRATION RATE; KIDNEY FUNCTION; MATHEMATICAL MODEL; NOTE;

EID: 0030772501     PISSN: 22965270     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218979     Document Type: Article

References (16)

1. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-1756
2. Lipp H-P. Bokemeyer C: Individuelle Carboplatin-dosierung. Anpassung an die Nierenfunktion. Arznei-mitteltherapie 1997;15:42-48.
3. Chatelut E. Canal P. Brunner V, Chevreau C. Pujol A. Boneu A, Roche H. Houin G. Bugat R: Prediction of Carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1995:87:573-580.
4. Desoizc B. Dufour R, Urien S, Kaltenbach M. Colin P: Evaluation of two dose individualisation methods for Carboplatin. Anticancer Res 1996:16:2073-2078.
5. Calvert AH. Boddy A, Bailey NP, Siddiqui N, Humphreys A, Hughes A, Robson L. Gumbrell L, Thomas H, Chapman F. Proctor M, Simmons D. Oakey A. Lind MJ, Sinha DV. Newell DR: Carboplatin in combination with paclitaxel in advanced ovarian cancer: Dose determination and pharmacokinetic and pharmacodynamic interactions Semin Oncol 1995:22:91-98.
6. Egorin MJ: Further Refinement of Carboplatin Dosing. J Natl Cancer Institute 1995:87:555-556.
7. Wada T, Nakamura T, Maeda Y, Maruyama H, Onishi Y, Hatae M: Actual Carboplatin AUC had better correlation with Chatelut's formula than arranged Calvert's formula using 24-hr creatinine clearance: Proc Am Soc Clin Oncol 1996;15:#1503.
8. Belani CP, Kim K, Bonomi P, Johnson D: Retrospective estimation of Carboplatin exposure by Calvert's and Chatelut's formulae and correlation with pharmacodynamic effects in metastatic nonsmall cell lung cancer (NSCLS): Proc Am Soc Clin Oncol 1996;15:#1119.
9. Chatelut E. Boddy AV. Peng B. Rubie H. Lavit M. Dezeuze A. Pearson AD, Roche H. Robert A. Newell DR, Canal P: Population pharmacokinetics of carboplatin in children. Clin Pharmacol Iher 1996:59:436-443.
10. Sorensen B. Stromgren A. Jakobsen P, Jakobsen A: Dose-toxicity relationship of carboplatin in combination with cyclophosphamide in ovarian cancer patients Cancer Chemother Pharmacol 1991;28: 397-401.
11. Jodrell DI, Egorin MJ. Canetta RM. Langcnberg P, Goldbloom EP, Burroughs JN, Goodlow JL. Tan S. Wiltshaw E: Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992:10:520-528.
12. Marina NM, Shema SJ, Bowman LC, Rodman J, Douglass EC. Furman WL, Pappo A, Santana VM, Hudson M. Meyer WH: Phase I study of escalating targeted dosis of carboplatin combined with ifosfa-mide and etoposide in children with relapsed solid tumors J Clin Oncol 1993:11:554-560.
13. Lampe H, Dearnaley DP, Price A, Mehta J, Powles R, Nicholls J, Horwich A: High-dose carboplatin and etoposide for salvage chemotherapy of germ cell tumours Eur J Cancer 1995:31A. 717-723.
14. Broun ER, Gonin R, Nichols CR, Einhorn LH: A retrospective analysis of carboplatin (CBDCA) area under the curve (AUC) in relation to toxicity and survival in testis cancer patients undergoing high dcse therapy (HDT) with autologous bone marror transplant (ABMT): Proc Am Soc Cin Oncol 1996;15:#703.
15. O'Reilly S, Walczak J, Egorin M, Zuhowski E, Goodman S, Kennedy MJ, Noga S, Braine H, Rowinsky E, Donehower R, Rosenhein N, Armstrong D: A phase 1 trial of high dose chemotherapy (HDC) with Cyclophosphamide (Cy) and AUC dosed Carboplatin (CBDCA) in advanced ovarian cancer using a continuous reassessment method for dose escalation. Proc Am Soc Clin Oncol 1996;15:#802.
16. Ozols RF, Kilpatrick D, O'Dywcr P, Johnson S, Bookman MA, Walczak J, Rowinsky E, McGuire WP: Phase I and pharmacokinetic study of Taxol (T) and carboplatin (C) in previously untreated patients (PTS) with advanced epithelial ovarian cancer (OC): A pilot study of the Gynecologic Oncology Group. Proc Am Soc Clin Oncol 1993;12:#824.